Brand inequity in access to COVID-19 vaccines.
作者信息
Sheel Meru, McEwen Samuel, Davies Sara E
机构信息
National Centre for Epidemiology and Population Health, Research School of Population Health, ANU College of Health and Medicine, the Australian National University, Canberra, Australia.
School of Public Health, the University of Sydney, Sydney, Australia.
出版信息
Lancet Reg Health West Pac. 2022 Jan;18:100366. doi: 10.1016/j.lanwpc.2021.100366. Epub 2022 Jan 1.
Abstract
摘要
相似文献
1
Brand inequity in access to COVID-19 vaccines.新冠疫苗获取方面的品牌不平等。
Lancet Reg Health West Pac. 2022 Jan;18:100366. doi: 10.1016/j.lanwpc.2021.100366. Epub 2022 Jan 1.
2
Uneven power dynamics must be levelled in COVID-19 vaccines access and distribution.在新冠疫苗的获取和分配方面，不均衡的权力动态必须得到平衡。
Public Health Pract (Oxf). 2021 Nov;2:100096. doi: 10.1016/j.puhip.2021.100096. Epub 2021 Feb 17.
3
In September 2020, the World Health Organization called for 'equitable access to COVID-19 tools' which included 'the development, production and equitable access to COVID-19 tests, treatments and vaccines globally, while strengthening health systems'. What evidence is there of inequity of access so far in this pandemic? What is the role of national governments and of the WHO in this?2020年9月，世界卫生组织呼吁“公平获取新冠病毒工具”，其中包括“在全球范围内研发、生产并公平获取新冠病毒检测手段、治疗方法和疫苗，同时加强卫生系统”。在这场大流行中，到目前为止有哪些获取方面不公平的证据？各国政府和世界卫生组织在此过程中分别扮演什么角色？
Med Confl Surviv. 2021 Sep;37(3):187-196. doi: 10.1080/13623699.2021.1969879.
4
In September 2020, the World Health Organization called for 'equitable access to COVID-19 tools' which included 'the development, production and equitable access to COVID-19 tests, treatments and vaccines globally, while strengthening health systems'. What evidence is there of inequity of access so far in this pandemic? What is the role of national governments and of the WHO in this?2020年9月，世界卫生组织呼吁“公平获取新冠疫情相关工具”，其中包括“在全球范围内研发、生产并公平获取新冠病毒检测手段、治疗方法和疫苗，同时加强卫生系统”。在这场大流行中，到目前为止有哪些获取方面不公平的证据？各国政府和世卫组织在此过程中分别扮演什么角色？
Med Confl Surviv. 2021 Sep;37(3):197-204. doi: 10.1080/13623699.2021.1969878. Epub 2021 Aug 25.
5
COVID-19 and Unmet Healthcare Needs of Older People: Did Inequity Arise in Europe?COVID-19 与老年人未满足的医疗保健需求：欧洲出现不平等了吗？
Int J Environ Res Public Health. 2021 Aug 31;18(17):9177. doi: 10.3390/ijerph18179177.
6
We need people's WHO to solve vaccine inequity, and we need it now.我们需要世界卫生组织来解决疫苗分配不公问题，而且现在就需要。
BMJ Glob Health. 2021 Jul;6(7). doi: 10.1136/bmjgh-2021-006598.
7
Trends in horizontal inequity in access to public health care services by immigrant condition in Spain (2006-2017).西班牙公共医疗服务获取方面的移民状况的水平不公平趋势（2006-2017 年）。
Int J Equity Health. 2019 Nov 29;18(1):185. doi: 10.1186/s12939-019-1092-1.
8
The impact of animosity, brand image, consumer boycott, and product judgment on made-in-China covid-19 vaccination intention.敌意、品牌形象、消费者抵制及产品评判对中国制造新冠疫苗接种意愿的影响。
Health Mark Q. 2021 Apr-Jul;38(2-3):150-167. doi: 10.1080/07359683.2021.1987010. Epub 2021 Oct 10.
9
COVID-19 Vaccine Booster: To Boost or Not to Boost.新冠疫苗加强针：打还是不打。
Infect Dis Rep. 2021 Oct 28;13(4):924-929. doi: 10.3390/idr13040084.
10
Data Mining on COVID-19 Vaccines: Side Effects.关于新冠疫苗的数据挖掘：副作用
Proc Assoc Inf Sci Technol. 2021;58(1):869-871. doi: 10.1002/pra2.592. Epub 2021 Oct 13.
引用本文的文献
1
COVID-19 vaccine preferences for pregnant and lactating women in Bangladesh and Kenya: a qualitative study.孟加拉国和肯尼亚孕妇和哺乳期妇女对 COVID-19 疫苗的偏好：一项定性研究。
Front Public Health. 2024 Aug 14;12:1412878. doi: 10.3389/fpubh.2024.1412878. eCollection 2024.
2
Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics.从 COVID-19 中吸取的教训，以降低全球南方的死亡率和发病率：为未来的大流行解决全球疫苗公平问题。
BMJ Glob Health. 2024 Jan 1;9(1):e013680. doi: 10.1136/bmjgh-2023-013680.
3
It is not too late to achieve global covid-19 vaccine equity.实现全球新冠疫苗公平分配还为时不晚。
BMJ. 2022 Mar 24;376:e070650. doi: 10.1136/bmj-2022-070650.
本文引用的文献
1
Vax the world.为世界接种疫苗。
Science. 2021 Nov 26;374(6571):1031. doi: 10.1126/science.abn3081. Epub 2021 Nov 25.
2
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.新冠病毒疫苗在中低收入国家的接受程度和犹豫。
Nat Med. 2021 Aug;27(8):1385-1394. doi: 10.1038/s41591-021-01454-y. Epub 2021 Jul 16.
3
Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.接种阿斯利康 ChAdOx1 nCoV-19（AZD1222）疫苗后出现伴血小板减少的血栓形成综合征（TTS）- 澳大利亚<60 岁人群的风险-效益分析。
Vaccine. 2021 Aug 9;39(34):4784-4787. doi: 10.1016/j.vaccine.2021.07.013. Epub 2021 Jul 10.
4
What's yours is ours: waiving intellectual property protections for COVID-19 vaccines.将知识产权保护让渡给 COVID-19 疫苗。
J Med Ethics. 2021 Sep;47(9):595-598. doi: 10.1136/medethics-2021-107555. Epub 2021 Jul 7.
5
A beautiful idea: how COVAX has fallen short.一个美好的设想：新冠疫苗全球获取机制（COVAX）为何未达预期。
Lancet. 2021 Jun 19;397(10292):2322-2325. doi: 10.1016/S0140-6736(21)01367-2.
6
Divergent vaccination policies could fuel mistrust and hesitancy.不同的疫苗接种政策可能会加剧不信任和犹豫情绪。
Lancet. 2021 Jun 19;397(10292):2333. doi: 10.1016/S0140-6736(21)01106-5. Epub 2021 Jun 1.
7
The precautionary principle, the AstraZeneca COVID-19 vaccine and mixed messaging.预防原则、阿斯利康新冠疫苗与信息传达不一致
J Paediatr Child Health. 2021 Apr;57(4):472-473. doi: 10.1111/jpc.15468.
8
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.确保全球公平获得 COVID-19 疫苗面临的挑战：生产、可负担性、分配和部署。
Lancet. 2021 Mar 13;397(10278):1023-1034. doi: 10.1016/S0140-6736(21)00306-8. Epub 2021 Feb 12.
Zotero 插件